ロード中...
Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma
Some patients with diffuse large B-cell lymphoma (DLBCL) present with a concurrent indolent lymphoma at diagnosis. Their outcomes in the rituximab era are not fully defined. Using a prospectively followed cohort of 1324 newly diagnosed DLBCL patients treated with immunochemotherapy, we defined the p...
保存先:
| 出版年: | Blood |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6888139/ https://ncbi.nlm.nih.gov/pubmed/31350266 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000858 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|